Is Tenaya Therapeutics, Inc. (TNYA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 7.1% / 30% | 32.0% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 7.1% / 33% | 32.0% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 11.3% / 33% | 51.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 7.1% / 33% | 32.0% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 11.3% / 33% | 51.2% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -83.8% | |
| Return on Assets (ROA) | -43.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$68M |
| Free Cash Flow | -$69M |
| Total Debt | $11M |
| Debt-to-Equity | 8.8 |
| Current Ratio | 6.8 |
| Total Assets | $147M |
Price & Trading
| Last Close | $0.70 |
| 50-Day MA | $0.74 |
| 200-Day MA | $1.02 |
| Avg Volume | 4.5M |
| Beta | 3.2 |
|
52-Week Range
$0.36
| |
About Tenaya Therapeutics, Inc. (TNYA)
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Tenaya Therapeutics, Inc. (TNYA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Tenaya Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Tenaya Therapeutics, Inc.'s debt ratio?
Tenaya Therapeutics, Inc.'s debt ratio is 7.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.3%.
What are Tenaya Therapeutics, Inc.'s key financial metrics?
Tenaya Therapeutics, Inc. has a market capitalization of $144M. Return on equity stands at -83.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.